Cell Impact (CI) Q2 2025 earnings summary

Executive summary

• Net sales for Q2 2025 were SEK 2.1 million, a 91% decrease year-over-year from SEK 23.8 million.

• Operating loss (EBIT) was SEK -20.0 million, slightly higher than SEK -19.6 million in Q2 2024.

• Rights issue completed during the quarter raised SEK 39.2 million before costs and loan repayment, securing short-term financing.

• Customer projects progressed, including a follow-up order from a leading Asian industrial company.

Financial highlights

• Net sales: SEK 2.1 million (Q2 2024: SEK 23.8 million).

• Operating loss (EBIT): SEK -20.0 million (Q2 2024: SEK -19.6 million).

• Net loss: SEK -21.2 million (Q2 2024: SEK -20.9 million).

• Cash flow from operating activities: SEK -11.9 million (Q2 2024: SEK -19.3 million).

• Cash and cash equivalents at period end: SEK 1.0 million (Q2 2024: SEK 22.6 million); SEK 16.1 million as of August 21, 2025.

Outlook and guidance

• Capital injection from rights issue provides financing until customer revenue can cover costs.

• Focus remains on scaling up industrial production and commercialization.

• Management expects growth as delayed major orders materialize.